Beam Therapeutics Inc (BEAM)

Etorro trading 970x250
Beam Therapeutics Inc (BEAM) Logo

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children’s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Beam Therapeutics Inc News and around…

Latest news about Beam Therapeutics Inc (BEAM) common stock and company :

Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
11 Jan, 2022 Yahoo! Finance

Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.

Top Stock Market News For Today January 11, 2021
11 Jan, 2022 FinancialContent
Expert Ratings For Beam Therapeutics
10 Jan, 2022 FinancialContent

Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the following analyst ratings: Bullish Somewhat ...

Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
10 Jan, 2022 Yahoo! Finance

The two companies will develop three treatments for genetic disease by correcting errors in our genes, using base-editing technology.

Pfizer announces deal worth up to $1.3 billion with Beam; Beam's stock is up 4.9%
10 Jan, 2022 Yahoo! Finance

Shares of Pfizer Inc. gained 0.2% in premarket trading on Monday after the company announced a deal with Beam Therapeutics Inc. worth up to $1.3 billion. Beam's stock was up 4.9% before the market opened. As part of the four-year agreement, the companies will use Beam's vivo base editing technology to develop drugs that treat rare genetic diseases of the liver, muscle, and central nervous system. Pfizer will pay Beam $300 million upfront; including milestone payments, the deal could be worth up

UPDATE 3-Pfizer CEO says Omicron-targeted vaccine is most likely outcome
10 Jan, 2022 Yahoo! Finance

Pfizer Inc Chief Executive Albert Bourla on Monday said a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant is likely needed and his company could have one ready to launch by March. Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a shot that would include both the previous vaccine as well as one targeted at the fast-spreading variant. "I think it is the most likely scenario," Bourla said, speaking at J.P. Morgan's annual healthcare conference, which is being held virtually this year.

Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
10 Jan, 2022 FinancialContent

Pfizer Inc(NYSE: PFE) andBeam Therapeutics Inc(NASDAQ: BEAM) haveannounced an exclusive four-year research ...

Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
10 Jan, 2022 FinancialContent

Pfizer is entering the CRISPR space through a $1.35 billion deal with Beam, the companies said Monday, in a deal sure to spark Beam stock.

Pfizer CEO says Omicron-targeted vaccine is most likely outcome
10 Jan, 2022 Yahoo! Finance

Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a shot that would include both the previous vaccine as well as one targeted at the fast-spreading variant. "I think it is the most likely scenario," Bourla said, speaking at J.P. Morgan's annual healthcare conference, which is being held virtually this year. Bourla said Pfizer could be ready to file for U.S. regulatory approval for a redesigned vaccine and launch it as soon as March.

Beam Therapeutics inks deal with Pfizer worth up to $1.35B
10 Jan, 2022 Yahoo! Finance

The Cambridge-based gene-editing firm has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc.

Beam Therapeutics Stock Active After $1.35 Billion Pfizer Drug Development Deal
10 Jan, 2022 Yahoo! Finance

Boston-based Beam Therapeutics has agreed to a potential $1.35 billion drug development deal with pharma giant Pfizer.

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
10 Jan, 2022 FinancialContent

Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.

Pfizer joins Beam Therapeutics to develop rare disease therapies
10 Jan, 2022 Yahoo! Finance

Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases. Beam will receive $300 million in upfront payment and lead research activities till three new therapy targets are selected for development from outside the firm's existing programs, the companies said on Monday. Pfizer will then be responsible for development and regulatory activities for the targets, with the option to opt in on exclusive, worldwide licenses for each.

My 3 Top Biotech Stock Picks for 2022
09 Jan, 2022 FinancialContent

These stocks are poised for a strong year.

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones
09 Jan, 2022 Yahoo! Finance

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia Nomination of Two Additional Development Candidates Anticipated in 2022 Company to Present Pipeline and Business Updates at 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET CAMBRIDGE, Mass., Jan. 09, 2022 (GLOBE NEWSWIR

IYY's Underlying Holdings Imply 12% Gain Potential
06 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
05 Jan, 2022 FinancialContent

Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:GOOS) was changed from Hold to Buy. Canada ...

Interesting BEAM Put And Call Options For August 19th
04 Jan, 2022 FinancialContent

Investors in Beam Therapeutics Inc (BEAM) saw new options begin trading this week, for the August 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 2:15 p.m. ET. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the present

Ershares Entrepreneurs Etf Buys Oracle Corp, Regeneron Pharmaceuticals Inc, Cintas Corp, Sells ...
28 Dec, 2021 Yahoo! Finance

Investment company Ershares Entrepreneurs Etf (Current Portfolio) buys Oracle Corp, Regeneron Pharmaceuticals Inc, Cintas Corp, ResMed Inc, Steel Dynamics Inc, sells Spotify Technology SA, Roku Inc, Exact Sciences Corp, Twist Bioscience Corp, Teladoc Health Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Ershares Entrepreneurs Etf.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
22 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. The post Top 5 Moonshots for 2022 Countdown: My No. 5 Pick appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

10 Best Genomics Stocks to Buy Now
17 Dec, 2021 Yahoo! Finance

In this article, we will discuss the 10 best genomics stocks to buy now. You can skip our detailed analysis of these stocks and go directly to the 5 Best Genomics Stocks to Buy Now. Genomics is the branch of biology that deals with the study of human genes. The genome is the complete set […]

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
12 Dec, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term development strategy for its base editing approach to treat sickle cell disease (SCD). The plan, and supportive data, are being presented during a Scientific Program Session oral presentation and two poster sessions at the 63rd American Society for Hematology (ASH) Annual Meeting & Exp

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
07 Dec, 2021 FinancialContent

These eight stocks could rebound nicely over the next year and beyond.

Got $1,000? Check Out These 3 Top Biotech Stocks
03 Dec, 2021 FinancialContent

Two big biotechs and one smaller one that could be winners over the long term.

Analysts Anticipate IYY Will Reach $127
01 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.

Direxion Launches New Nanotechnology ETF, TYNE
23 Nov, 2021 FinancialContent

On Tuesday, Direxion announced the launch of the Direxion Nanotechnology ETF (TYNE). TYNE invests in companies believed to be at the forefront of nanotechnology, spanning the traditional sectors of consumer discretionary, healthcare, industrials, information technology, and materials....

Being First Is Not Enough For Crispr Therapeutics
15 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. The post Being First Is Not Enough For Crispr Therapeutics appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
12 Nov, 2021 FinancialContent

Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house ...

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies
12 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical research demonstrating the ability of the company’s multiplex edited CAR T cells to target CD5-positive tumors, leading to tumor clearance in vivo. The data are highlighted in a poster titled, “CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy

Beam Therapeutics Inc (BEAM) is a NASDAQ Common Stock listed in , ,

970x250